Sign in

CIK 0002012593 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Rapport Therapeutics, Inc.

Sign in to watch
Ticker
RAPP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
880724208
Phone
857-321-8020
Business address
99 HIGH STREET, SUITE 2100, BOSTON, MA, 02110
Former names
Rapport Therapeutics, Inc.
  1. 4 Planned sale Chief Scientific Officer sold 8,500 shares at an average $29.02 ($246,655)
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Planned sale Chief Executive Officer sold 10,916 shares at an average $26.11 ($285,071)
  9. 4 Planned sale Chief Scientific Officer sold 8,500 shares at an average $26.84 ($228,132)
  10. 4 Open-market sale Chief Scientific Officer sold 6,567 shares at $30.05 ($197,338)
  11. 4 Open-market sale Chief Development Officer sold 2,840 shares at $30.05 ($85,342)
  12. 4 Planned sale Chief Executive Officer sold 10,916 shares at an average $29.64 ($323,508)
  13. 4 Planned sale Chief Scientific Officer sold 8,500 shares at an average $30.02 ($255,130)
  14. 4 Planned sale Chief Operating Officer sold 5,000 shares at $30.10 ($150,487)
  15. 4 Planned sale Chief Executive Officer sold 10,916 shares at an average $25.20 ($275,047)
  16. 4 Planned sale Chief Scientific Officer sold 8,500 shares at an average $25.19 ($214,091)
  17. 4 Planned sale Chief Scientific Officer sold 8,500 shares at an average $25.79 ($219,196)
  18. 4 Planned sale Chief Executive Officer sold 10,916 shares at an average $25.81 ($281,729)
  19. 4 Planned sale Chief Executive Officer sold 76,420 shares at an average $26.32 ($2,011,197)
  20. 4 Planned sale Chief Scientific Officer sold 8,500 shares at an average $24.19 ($205,649)

Page 3 of 6 · 120 filings